CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies - Press Release

- CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients - Dur

Related Keywords

Illinois ,United States ,Chicago ,American ,Markus Renschler ,Ryanc Lynch ,Fred Hutchinson Cancer Center ,Exchange Commission ,Linkedin ,American Society Of Clinical Oncology ,Twitter ,Cyteir Therapeutics Inc ,Advanced Solid ,Clinical Oncology ,Chief Executive Officer ,Assistant Professor ,Action Insights Have Potential ,Additional Tumor ,Ongoing Phase ,Expansion Cohorts ,Study Expected ,Cyteir Therapeutics ,Annual Report ,